S-Isopropyl-N-acetyl-L-cysteine | 5572-21-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: S-Isopropyl-N-acetyl-L-cysteine
• 英文别名: N-Acetyl-S-isopropyl-L-cystein；N-Acetyl-S-propan-2-yl-L-cysteine；(2R)-2-acetamido-3-propan-2-ylsulfanylpropanoic acid
• CAS: 5572-21-4
• 化学式: C₈H₁₅NO₃S
• 分子量: 205.278
• InChiKey: SSYUDPJWXJZUAP-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  91.7
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2930909090

反应信息

• 作为反应物：
  描述：

  S-Isopropyl-N-acetyl-L-cysteine 在 pig kidney acylase I 作用下， 以 phosphate buffer 为溶剂， 反应 0.17h， 生成 S-Isopropyl-L-cystein
  参考文献：
  名称：

  Acylase I-Catalyzed Deacetylation of N-Acetyl-l-cysteine and S-Alkyl-N-acetyl-l-cysteines

  摘要：

  The aminoacylase that catalyzes the hydrolysis of N-acetyl-L-cysteine (NAC) was identified as acylase I after purification by column chromatography and electrophoretic analysis. Rat kidney cytosol was fractionated by ammonium sulfate precipitation, and the proteins were separated by ion-exchange column chromatography, gel-filtration column chromatography, and hydrophobic interaction column chromatography. Acylase activity with NAC and N-acetyl-L-methionine (NAM), a known substrate for acylase I, as substrates coeluted during all chromatographic steps. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed that the protein was purified to near homogeneity and had a subunit M-r of 43 000, which is identical with the M-r of acylase I from porcine kidney and bovine liver. n-Butylmalonic acid was a slow-binding inhibitor of acylase I and inhibited the deacetylation of NAC with a K-i of 192 +/- 27 mu M These results show that acylase I catalyzes the deacetylation of NAG. The acylase I-catalyzed deacetylation of a range of S-alkyl-N-acetyl-L-cysteines, their carbon and oxygen analogues, and the selenium analogue of NAM was also studied with porcine kidney acylase I. The specific activity of the acylase I-catalyzed deacetylation of these substrates was related to their calculated molar volumes and lag P values. The S-alkyl-N-acetyl-L-cysteines with short (C-0-C-3) and unbranched S-alkyl substituents were good acylase I substrates, whereas the S-alkyl-N-acetyl-L-cysteines with long (>C-3) and branched S-alkyl substituents were poor acylase I substrates. The carbon and oxygen analogues of S-methyl-N-acetyl-L-cysteine and the carbon analogue of S-ethyl-N-acetyl-L-cysteine were poor acylase I substrates, whereas the selenium analogue of NAM was a good acylase I substrate.

  DOI：

  10.1021/tx980018b
• 作为产物：
  描述：

  N-乙酰-L-半胱氨酸 、 2-溴丙烷 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 4.0h， 以58%的产率得到S-Isopropyl-N-acetyl-L-cysteine
  参考文献：
  名称：

  An improved method for cysteine alkylation

  摘要：

  An improved method for the synthesis of S-alkylated cysteine derivatives with branched alkyl chains is reported. These compounds can be obtained in good yield and high purity by refluxing the cysteine thiol with the appropriate alkyl bromide in a solution of sodium ethoxide in ethanol. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(01)00098-3

文献信息

• ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF
  申请人：Scicinski Jan

  公开号：US20140349988A1

  公开（公告）日：2014-11-27

  The invention provides organonitro thioether compounds, compositions containing such compounds, isolated organonitro thioether compounds and methods for using such compounds and compositions to treat cancer in a patient. Exemplary organonitro thioether compounds described herein include 2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl thioethers and variants thereof. Another aspect of the invention provides a pharmaceutical composition, comprising a pharmaceutically acceptable carrier and an organonitro thioether compound described herein, such as a compound of Formula I or II. Another aspect of the invention provides a method of treating cancer in a patient. The method comprises administering to a patient in need thereof a therapeutically effective amount of an organonitro thioether compound described herein, such as a compound of Formula I or II, to treat the cancer.

  本发明提供了有机硝基硫醚化合物，含有这种化合物的组合物，分离的有机硝基硫醚化合物以及使用这种化合物和组合物治疗患者的方法。本文描述的示例有机硝基硫醚化合物包括2-（3,3-二硝基氮杂环丙烷-1-基）-2-氧乙基硫醚及其变体。本发明的另一个方面提供了一种制药组合物，包括一种药学上可接受的载体和本文所述的有机硝基硫醚化合物，例如式I或II的化合物。本发明的另一个方面提供了一种治疗患者癌症的方法。该方法包括向需要治疗癌症的患者施用本文所述的有机硝基硫醚化合物的治疗有效量，例如式I或II的化合物，以治疗癌症。
• Lincomycin biosynthetic intermediates, method for preparation, and use thereof
  申请人：SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES

  公开号：US10590159B2

  公开（公告）日：2020-03-17

  Provided in the present invention are a class of Lincomycin biosynthetic intermediates and a preparation method and use thereof. Specifically provided are Lincomycin biosynthetic intermediates obtained from the genetic modification of a Lincomycin producing bacterium, and a method for the production thereof through fermentation and purification through separation.

  本发明提供了一类林可霉素生物合成中间体及其制备方法和用途。具体地说，本发明提供了通过对林可霉素生产菌进行基因改造而获得的林可霉素生物合成中间体，以及通过发酵和分离纯化生产林可霉素生物合成中间体的方法。
• Therapeutic compounds and methods
  申请人：Regents of the University of Minnesota

  公开号：US11479579B2

  公开（公告）日：2022-10-25

  Disclosed herein are compounds of formula I: (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, and R3 may any of the values defined herein, as well as compositions comprising such compounds. Also disclosed are methods for treating diseases including neurodegenerative disorders such as Parkinson's Disease and Alzheimer's Disease.

  本文公开了式 I：(I) 的化合物或其药学上可接受的盐类，其中 R1、R2 和 R3 可为本文定义的任何值，以及包含此类化合物的组合物。还公开了治疗包括神经退行性疾病（如帕金森病和阿尔茨海默病）在内的疾病的方法。
• Use of Compounds Elevating Glutathione Levels for the Treatment of Autism, Autistic Spectrum Disorders and Fragile X Syndrome
  申请人：Promentis Pharmaceuticals, Inc.

  公开号：US20150045312A1

  公开（公告）日：2015-02-12

  Methods of treating autism, autistic spectrum disorders or Fragile X syndrome comprised of administering molecules that engage the cystine-glutamate exchange (System x c − ) and/or elevate the extracellular levels of glutathione in the CNS. Preferred compounds are cysteine/cystine prodrugs or N-acetyl cysteine (NAC) prodrugs.
• Cysteine Prodrugs
  申请人：Lawton Daniel

  公开号：US20160081987A1

  公开（公告）日：2016-03-24

  Novel cysteine prodrugs and their use in the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of the Central Nervous System (CNS), including but not limited to schizophrenia, drug craving, drug addiction, bipolar disorder, anxiety, depression, Parkinson's disease, Alzheimer's disease, cognitive dysfunction, multiple sclerosis, Amyotrophic lateral sclerosis (ALS), ischemic stroke, HIV dementia, and Huntington's disease.